Shenzhen Jindu Biomedical Technology Co., Ltd. has recently proclaimed the successful closure of a Pre-A+ round financing, amassing tens of millions, with Nanshan Venture Capital as the key investor. Since its inception in 2022, the company has swiftly ascended to a position of global prominence in the realm of AI-driven bioscience. Harnessing the power of its BioFord™ AI biological research platform and the GeneLLM® multi-omics large model system, Jindu Biotech is vigorously propelling the evolution of life sciences. The team at Jindu Biotech has transcended the confines of conventional research methodologies, forging a comprehensive chain of solutions. Their platform has already been deployed across several premier institutions. The R&D contingent, helmed by alumni from Oxford, boasts substantial core technological prowess. Beyond its proprietary GeneLLM large model, Jindu Biotech has engineered a suite of AI platforms and services, catering to a broad spectrum of applications and attracting a multitude of clients. The company's visionary founder and CEO, Jin Yongcheng, who holds a Ph.D. in Biomedical Engineering from the University of Oxford, has authored numerous scholarly articles and pioneered the development of the medical diagnostic AI large model GeneLLM, with the ambitious goal of attaining diagnostic capabilities on par with those of a seasoned physician.